0.00

100.00% -8.22

Biophytis ADR (BPTS)

Overview News Price History Discussions Forecast Stock Split

Biophytis ADR stock is currently priced at $0.00, with a 24-hour trading volume of 0. It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $8.41 pivot point. If it approaches the $6.95 support level, significant changes may occur.

Previous Close:

$8.22

Open:

24h Volume:

Market Cap:

$2.36M

Revenue:

Net Income/Loss:

$-20.55M

P/E Ratio:

0.00

EPS:

-8.316

Net Cash Flow:

$-18.09M

1W Performance:

-100.00%

1M Performance:

-100.00%

6M Performance:

-100.00%

1Y Performance:

-100.00%

1D Range:

$0.00

52W Range:

$0.00

$10.19

Biophytis ADR Stock (BPTS) Company Profile

Name

Biophytis ADR

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

33 1 44 27 23 00

Address

Sorbonne University, BC 9, BAtiment A 4Eme Etage 4 place Jussieu Cedex 05, Paris

Employee

Twitter

Next Earnings Date

Latest SEC Filings

BPTS's Discussions on Twitter

Biophytis ADR Stock (BPTS) Latest News

Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

Benzinga

Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

Benzinga

Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Dow Dips 150 Points; Laser Photonics Shares Spike Higher

Benzinga

Biophytis (BPTS) to Begin Phase II Obesity Study, Stock Up

Zacks Investment Research

Biophytis ADR Stock (BPTS) Financials Data

Biophytis ADR (BPTS) Net Income 2024

BPTS net income (TTM) was -$20.55 million for the quarter ending June 30, 2023, a +31.62% increase year-over-year.

Biophytis ADR (BPTS) Cash Flow 2024

BPTS recorded a free cash flow (TTM) of -$18.09 million for the quarter ending June 30, 2023, a +36.36% increase year-over-year.

Biophytis ADR (BPTS) Earnings per Share 2024

BPTS earnings per share (TTM) was -$8.316 for the quarter ending June 30, 2023, a +70.77% growth year-over-year.

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.